EGFR and lung adenocarcinoma: Parallel statistical evaluations demonstrated that, in our patient cohort, there were no differences in OS of patients with EGFR mutated lung adenocarcinoma versus those with EGFR wild-type tumors, irrespective of the stage (p = 0.9875).